Supernus Pharmaceuticals (SUPN) Operating Income (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Operating Income of -$58.0 million for Q2 2026, down 577.42% year-over-year from $12.1 million in Q2 2025, and down 1372.26% on a QoQ basis from -$3.9 million in Q4 2025.
Supernus Pharmaceuticals (SUPN) Operating Income (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Operating Income for 16 years, with the latest figure at -$58.0 million in Q2 2026.
- Operating Income for Q2 2026 came in at -$58.0 million, down 577.42% year-over-year; the trailing twelve-month figure through Jun 2026 was -$110.0 million (down 271.5% YoY), and the FY2025 annual result was -$62.3 million, down 176.27% from the prior year.
- Operating Income slipped to -$58.0 million in Q2 2026, from -$3.9 million in the prior quarter.
- Over five years, Operating Income peaked at $40.8 million in Q3 2024 and troughed at -$60.2 million in Q3 2025.
- A 5-year average of $133823.5 and a median of $2.0 million in 2022 frame the typical range for Operating Income.
- The widest annual swing landed in 2024, when Operating Income surged 2249.1%; it then plunged 577.42% in 2026.
- A 5-year view of Operating Income shows it stood at $34.3 million in 2022, then plunged by 102.9% to -$996000.0 in 2023, then surged by 2249.1% to $21.4 million in 2024, then sank by 118.39% to -$3.9 million in 2025, then plunged by 1372.26% to -$58.0 million in 2026.
- Per Business Quant data, the three most recent Operating Income figures were -$58.0 million in Q2 2026, -$3.9 million in Q4 2025, and -$60.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -231.00 Mn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 837.00 Mn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 1.26 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 330.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 6.30 Mn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 151.50 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 248.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.76 Bn | 2.39 Bn | 185.39 Mn | -57.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -57.96 Mn |
| Dec 31, 2025 | -3.94 Mn |
| Sep 30, 2025 | -60.23 Mn |
| Jun 30, 2025 | 12.14 Mn |
| Mar 31, 2025 | -10.26 Mn |
| Dec 31, 2024 | 21.41 Mn |
| Sep 30, 2024 | 40.85 Mn |
| Jun 30, 2024 | 22.57 Mn |
| Mar 31, 2024 | -3.15 Mn |
| Dec 31, 2023 | -996,000.00 |
| Sep 30, 2023 | 8.14 Mn |
| Jun 30, 2023 | -17.59 Mn |
| Mar 31, 2023 | 5.18 Mn |
| Dec 31, 2022 | 34.33 Mn |
| Sep 30, 2022 | -1.52 Mn |
| Jun 30, 2022 | 11.35 Mn |
| Mar 31, 2022 | 1.97 Mn |
| Dec 31, 2021 | 6.10 Mn |
| Sep 30, 2021 | 32.60 Mn |
| Jun 30, 2021 | 34.11 Mn |